Eli Lilly and Company

NYSE:LLY | Last Update: Jun 16, 2025
user-image

Essential Information

Market Cap
$902.88B
Latest Price
$819.36
Fair Value*
P/E Ratio
66.67
SS Score*
Div. Yield
0.73%
WACC
5.71%
P/FCF Ratio
196.86
*This is not investment advice

Financial Summary (TTM)

Fiscal Year: January - December

Revenue
Net Income
Free Cash Flow
Shares Outstanding
EPS
ROIC
Dividend Per Share
Debt/FCF

In-Depth Analysis of Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY), listed on the NYSE, has a market capitalization of $902.88B. As of Jun 16, 2025, the stock is trading at $819.36 per share, offering investors a clear view of its current market value. Eli Lilly and Company is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.

With a P/E ratio of 66.67, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Eli Lilly and Company also offers a dividend yield of 0.73%, making it an attractive option for income-focused investors who seek regular dividends.

Our Discounted Cash Flow (DCF) analysis reveals that Eli Lilly and Company (LLY) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.

The proprietary SS Score for Eli Lilly and Company is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.

To view the detailed SS Score for Eli Lilly and Company, Login or Upgrade for access.

The Price to Free Cash Flow (P/FCF) ratio for Eli Lilly and Company is 196.86, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.

In summary, Eli Lilly and Company (LLY) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.

*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.

Frequently Asked Questions about Eli Lilly and Company (LLY)

Is Eli Lilly and Company a good stock to buy?

Whether Eli Lilly and Company (LLY) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.

What is the fair value of Eli Lilly and Company?

The fair value of Eli Lilly and Company (LLY) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.

What is Eli Lilly and Company's SS Score?

The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Eli Lilly and Company. To access the full SS Score, consider upgrading your subscription.

How does Eli Lilly and Company compare to other stocks in the industry sector?

Eli Lilly and Company is a significant player in the industry sector, with a market capitalization of $902.88B and a competitive P/E ratio of 66.67. Investors should compare these metrics with industry peers to gauge whether Eli Lilly and Company is outperforming or underperforming within its sector.

News about Eli Lilly and Company (LLY)

10 days agoCNBC Television

Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology

CNBC's Angelica Peebles sits down with Lilly's Head of Oncology, Jake Van Naarden, to discuss what's next in Lilly's oncology pipeline and what Lilly is changing about its clinical trials to make them...

Forbes

LLY Stock Too Cheap At $750?

Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn't, especially when you consider three simple facts:

13 days agoSchwab Network

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.

Seeking Alpha

5 Alpha Generating Monsters

Any stock can generate alpha, but doing it consistently is rare. These 5 stocks have delivered alpha for 4 out of the last 5 years. Valuation is important, so I screen for it and eliminate overpriced ...

Reuters

Eli Lilly to acquire privately held SiteOne

Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.

Our content is for educational use only, not investment advice. By using it, you agree to our Terms of Use.